Which has higher valuation and earnings, AZTA or SLP?

Azenta has higher revenue and earnings than Simulations Plus. Azenta is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Azenta $593.82M 2.43 -$55.76M -$2.76 N/A Simulations Plus $79.18M 4.70 -$64.72M $0.40 45.98

Is AZTA or SLP more profitable?

Simulations Plus has a net margin of 9.88% compared to Azenta's net margin of -20.63%. Simulations Plus' return on equity of 13.50% beat Azenta's return on equity. Company Net Margins Return on Equity Return on Assets Azenta -20.63% 1.18% 0.97% Simulations Plus 9.88% 13.50% 12.45%

Does the media refer more to AZTA or SLP?

In the previous week, Azenta had 13 more articles in the media than Simulations Plus. MarketBeat recorded 18 mentions for Azenta and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.45 beat Azenta's score of 1.10 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Azenta 11 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SLP or CYRX?

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $79.18M 4.70 -$64.72M $0.40 45.98 CryoPort $176.18M 4.63 $78.30M -$0.90 N/A

Does the media favor SLP or CYRX?

In the previous week, Simulations Plus had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for CryoPort. CryoPort's average media sentiment score of 1.84 beat Simulations Plus' score of 1.45 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CryoPort 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to MLAB or SLP?

In the previous week, Simulations Plus had 1 more articles in the media than Mesa Laboratories. MarketBeat recorded 5 mentions for Simulations Plus and 4 mentions for Mesa Laboratories. Simulations Plus' average media sentiment score of 1.45 beat Mesa Laboratories' score of 1.41 indicating that Simulations Plus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesa Laboratories 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, SLP or OABI?

Simulations Plus has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $79.18M 4.70 -$64.72M $0.40 45.98 OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A

Is SLP or OABI more profitable?

Simulations Plus has a net margin of 9.88% compared to OmniAb's net margin of -115.12%. Simulations Plus' return on equity of 13.50% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% OmniAb -115.12% -16.59% -14.82%

Does the media favor SLP or OABI?

In the previous week, OmniAb had 3 more articles in the media than Simulations Plus. MarketBeat recorded 8 mentions for OmniAb and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.45 beat OmniAb's score of 0.76 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OmniAb 2 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, SLP or EVO?

Simulations Plus has higher earnings, but lower revenue than Evotec. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Simulations Plus $79.18M 4.70 -$64.72M $0.40 45.98 Evotec $891.97M 0.76 -$117.12M N/A N/A

Is SLP or EVO more profitable?

Simulations Plus has a net margin of 9.88% compared to Evotec's net margin of -26.20%. Simulations Plus' return on equity of 13.50% beat Evotec's return on equity. Company Net Margins Return on Equity Return on Assets Simulations Plus 9.88% 13.50% 12.45% Evotec -26.20% -24.93% -11.35%

Does the media prefer SLP or EVO?

In the previous week, Simulations Plus and Simulations Plus both had 5 articles in the media. Simulations Plus' average media sentiment score of 1.45 beat Evotec's score of -0.03 indicating that Simulations Plus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Simulations Plus 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Simulations Plus (SLP) Competitors

$18.39 -0.03 (-0.16%)

As of 08/28/2026 04:00 PM Eastern

Compare

SLP vs. AZTA, CYRX, MLAB, OABI, and EVO

Should you buy Simulations Plus stock or one of its competitors? Simulations Plus's main competitors and comparable companies include Azenta (AZTA), CryoPort (CYRX), Mesa Laboratories (MLAB), OmniAb (OABI), and Evotec (EVO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Simulations Plus compare to Azenta?

Azenta (NASDAQ:AZTA) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Azenta has higher revenue and earnings than Simulations Plus. Azenta is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Azenta	$593.82M	2.43	-$55.76M	-$2.76	N/A
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	45.98

Simulations Plus has a net margin of 9.88% compared to Azenta's net margin of -20.63%. Simulations Plus' return on equity of 13.50% beat Azenta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Azenta	-20.63%	1.18%	0.97%
Simulations Plus	9.88%	13.50%	12.45%

In the previous week, Azenta had 13 more articles in the media than Simulations Plus. MarketBeat recorded 18 mentions for Azenta and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.45 beat Azenta's score of 1.10 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Azenta	11 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Azenta currently has a consensus price target of $41.20, suggesting a potential upside of 25.04%. Simulations Plus has a consensus price target of $17.25, suggesting a potential downside of 6.20%. Given Azenta's stronger consensus rating and higher possible upside, equities research analysts plainly believe Azenta is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Azenta	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

99.1% of Azenta shares are held by institutional investors. Comparatively, 78.1% of Simulations Plus shares are held by institutional investors. 10.9% of Azenta shares are held by company insiders. Comparatively, 19.1% of Simulations Plus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Azenta has a beta of 1.36, meaning that its share price is 36% more volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Summary

Azenta and Simulations Plus tied by winning 8 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to CryoPort?

Simulations Plus (NASDAQ:SLP) and CryoPort (NASDAQ:CYRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, analyst recommendations, profitability, dividends, institutional ownership and risk.

Simulations Plus currently has a consensus price target of $17.25, suggesting a potential downside of 6.20%. CryoPort has a consensus price target of $18.00, suggesting a potential upside of 11.87%. Given CryoPort's stronger consensus rating and higher probable upside, analysts plainly believe CryoPort is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
CryoPort	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 92.9% of CryoPort shares are held by institutional investors. 19.1% of Simulations Plus shares are held by insiders. Comparatively, 9.5% of CryoPort shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Simulations Plus has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market. Comparatively, CryoPort has a beta of 1.89, suggesting that its stock price is 89% more volatile than the broader market.

Simulations Plus has a net margin of 9.88% compared to CryoPort's net margin of -20.05%. Simulations Plus' return on equity of 13.50% beat CryoPort's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
CryoPort	-20.05%	-7.20%	-4.30%

In the previous week, Simulations Plus had 3 more articles in the media than CryoPort. MarketBeat recorded 5 mentions for Simulations Plus and 2 mentions for CryoPort. CryoPort's average media sentiment score of 1.84 beat Simulations Plus' score of 1.45 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CryoPort	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

CryoPort has higher revenue and earnings than Simulations Plus. CryoPort is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	45.98
CryoPort	$176.18M	4.63	$78.30M	-$0.90	N/A

Summary

Simulations Plus and CryoPort tied by winning 8 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Mesa Laboratories?

Mesa Laboratories (NASDAQ:MLAB) and Simulations Plus (NASDAQ:SLP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

Mesa Laboratories has a beta of 0.92, indicating that its share price is 8% less volatile than the broader market. Comparatively, Simulations Plus has a beta of 1.32, indicating that its share price is 32% more volatile than the broader market.

Mesa Laboratories presently has a consensus price target of $110.00, suggesting a potential downside of 14.79%. Simulations Plus has a consensus price target of $17.25, suggesting a potential downside of 6.20%. Given Simulations Plus' higher possible upside, analysts plainly believe Simulations Plus is more favorable than Mesa Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesa Laboratories	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88

Mesa Laboratories has higher revenue and earnings than Simulations Plus. Simulations Plus is trading at a lower price-to-earnings ratio than Mesa Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesa Laboratories	$249.13M	2.90	$6.71M	$0.84	153.68
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	45.98

90.6% of Mesa Laboratories shares are owned by institutional investors. Comparatively, 78.1% of Simulations Plus shares are owned by institutional investors. 2.8% of Mesa Laboratories shares are owned by company insiders. Comparatively, 19.1% of Simulations Plus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Simulations Plus had 1 more articles in the media than Mesa Laboratories. MarketBeat recorded 5 mentions for Simulations Plus and 4 mentions for Mesa Laboratories. Simulations Plus' average media sentiment score of 1.45 beat Mesa Laboratories' score of 1.41 indicating that Simulations Plus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesa Laboratories	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Simulations Plus has a net margin of 9.88% compared to Mesa Laboratories' net margin of 1.92%. Mesa Laboratories' return on equity of 22.72% beat Simulations Plus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesa Laboratories	1.92%	22.72%	9.82%
Simulations Plus	9.88%	13.50%	12.45%

Summary

Simulations Plus beats Mesa Laboratories on 8 of the 15 factors compared between the two stocks.

How does Simulations Plus compare to OmniAb?

Simulations Plus (NASDAQ:SLP) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Simulations Plus has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

78.1% of Simulations Plus shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 19.1% of Simulations Plus shares are held by company insiders. Comparatively, 9.8% of OmniAb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Simulations Plus presently has a consensus target price of $17.25, suggesting a potential downside of 6.20%. OmniAb has a consensus target price of $11.00, suggesting a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher possible upside, analysts clearly believe OmniAb is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, OmniAb had 3 more articles in the media than Simulations Plus. MarketBeat recorded 8 mentions for OmniAb and 5 mentions for Simulations Plus. Simulations Plus' average media sentiment score of 1.45 beat OmniAb's score of 0.76 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OmniAb	2 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Simulations Plus has a net margin of 9.88% compared to OmniAb's net margin of -115.12%. Simulations Plus' return on equity of 13.50% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
OmniAb	-115.12%	-16.59%	-14.82%

Simulations Plus has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Simulations Plus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	45.98
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Summary

Simulations Plus beats OmniAb on 11 of the 16 factors compared between the two stocks.

How does Simulations Plus compare to Evotec?

Simulations Plus (NASDAQ:SLP) and Evotec (NASDAQ:EVO) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Simulations Plus has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market. Comparatively, Evotec has a beta of 1.96, indicating that its stock price is 96% more volatile than the broader market.

78.1% of Simulations Plus shares are owned by institutional investors. Comparatively, 5.8% of Evotec shares are owned by institutional investors. 19.1% of Simulations Plus shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Simulations Plus and Simulations Plus both had 5 articles in the media. Simulations Plus' average media sentiment score of 1.45 beat Evotec's score of -0.03 indicating that Simulations Plus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Simulations Plus	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evotec	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Simulations Plus has a net margin of 9.88% compared to Evotec's net margin of -26.20%. Simulations Plus' return on equity of 13.50% beat Evotec's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Simulations Plus	9.88%	13.50%	12.45%
Evotec	-26.20%	-24.93%	-11.35%

Simulations Plus has higher earnings, but lower revenue than Evotec.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Simulations Plus	$79.18M	4.70	-$64.72M	$0.40	45.98
Evotec	$891.97M	0.76	-$117.12M	N/A	N/A

Simulations Plus presently has a consensus price target of $17.25, suggesting a potential downside of 6.20%. Evotec has a consensus price target of $3.00, suggesting a potential upside of 57.07%. Given Evotec's stronger consensus rating and higher probable upside, analysts clearly believe Evotec is more favorable than Simulations Plus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Simulations Plus	1 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.88
Evotec	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Summary

Simulations Plus beats Evotec on 8 of the 13 factors compared between the two stocks.

Get Simulations Plus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SLP vs. The Competition

Export

Metric	Simulations Plus	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$371.93M	$10.11B	$7.21B	$12.90B
Dividend Yield	N/A	1.46%	2.54%	11.28%
P/E Ratio	45.98	62.76	273.16	25.42
Price / Sales	4.70	111.84	630.81	94.42
Price / Cash	12.85	26.70	28.74	36.03
Price / Book	2.97	5.49	11.08	6.36
Net Income	-$64.72M	$56.67B	$3.48B	$349.79M
7 Day Performance	-0.05%	-1.52%	0.13%	-0.80%
1 Month Performance	0.49%	7.21%	7.08%	4.13%
1 Year Performance	29.78%	24.31%	24.67%	15.17%

Simulations Plus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SLP Simulations Plus	1.2027 of 5 stars	$18.39 -0.2%	$17.25 -6.2%	+29.8%	$371.93M	$79.18M	45.98	160	News Coverage Positive News
AZTA Azenta	3.0178 of 5 stars	$33.68 +2.4%	$41.20 +22.3%	+7.9%	$1.48B	$613.81M	N/A	3,000	News Coverage Positive News Analyst Upgrade
CYRX CryoPort	2.1723 of 5 stars	$16.66 +1.9%	$18.00 +8.1%	+81.6%	$845.15M	$176.18M	N/A	1,186
MLAB Mesa Laboratories	1.4912 of 5 stars	$124.53 +0.2%	$110.00 -11.7%	+90.5%	$697.37M	$249.13M	148.25	680	Positive News
OABI OmniAb	2.483 of 5 stars	$4.74 +0.5%	$11.00 +132.3%	+179.4%	$687.00M	$38.46M	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SLP) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Simulations Plus (SLP) Competitors

SLP vs. AZTA, CYRX, MLAB, OABI, and EVO

How does Simulations Plus compare to Azenta?

Summary

How does Simulations Plus compare to CryoPort?

Summary

How does Simulations Plus compare to Mesa Laboratories?

Summary

How does Simulations Plus compare to OmniAb?

Summary

How does Simulations Plus compare to Evotec?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Simulations Plus (SLP) Competitors

SLP vs. AZTA, CYRX, MLAB, OABI, and EVO

How does Simulations Plus compare to Azenta?

Which has higher valuation and earnings, AZTA or SLP?

Is AZTA or SLP more profitable?

Does the media refer more to AZTA or SLP?

Do analysts recommend AZTA or SLP?

Do insiders & institutionals hold more shares of AZTA or SLP?

Which has more volatility and risk, AZTA or SLP?

Summary

How does Simulations Plus compare to CryoPort?

Do analysts recommend SLP or CYRX?

Do insiders and institutionals hold more shares of SLP or CYRX?

Which has more volatility & risk, SLP or CYRX?

Is SLP or CYRX more profitable?

Does the media favor SLP or CYRX?

Which has better valuation and earnings, SLP or CYRX?

Summary

How does Simulations Plus compare to Mesa Laboratories?

Which has more volatility & risk, MLAB or SLP?

Do analysts rate MLAB or SLP?

Which has better earnings & valuation, MLAB or SLP?

Do institutionals and insiders hold more shares of MLAB or SLP?

Does the media refer more to MLAB or SLP?

Is MLAB or SLP more profitable?

Summary

How does Simulations Plus compare to OmniAb?

Which has more volatility and risk, SLP or OABI?

Do insiders and institutionals have more ownership in SLP or OABI?

Do analysts rate SLP or OABI?

Does the media favor SLP or OABI?

Is SLP or OABI more profitable?

Which has stronger earnings & valuation, SLP or OABI?

Summary

How does Simulations Plus compare to Evotec?

Which has more volatility and risk, SLP or EVO?

Do insiders & institutionals have more ownership in SLP or EVO?

Does the media prefer SLP or EVO?

Is SLP or EVO more profitable?

Which has stronger valuation and earnings, SLP or EVO?

Do analysts recommend SLP or EVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLP vs. The Competition

Simulations Plus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools